How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced solid tumor cancer with a specific TP53 Y220C mutation confirmed by a genetic test.
- You are in good enough health to walk and take care of yourself (ECOG score 0 or 1).
- You have not had certain cancer treatments or taken medicines that might interfere with the study drugs in the past few weeks.
- You do not have other serious health problems like uncontrolled heart disease, active infections, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
This trial is testing a new tablet called YY2201 for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help shrink or control the tumor.
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Hear when a new TP53 Y220C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.